Our XenoProt™ platform reads the fundamental physics of how proteins interact — directly from amino acid sequence alone. By decoding these relationships from first principles, we discover peptide therapeutics that are more specific, more effective, and more likely to reach the clinic.
The pharma industry spends $28 billion a year on high-throughput screening. For peptides, most of that is waste. R&D budgets keep climbing, but discovery output stays flat.
Million-compound libraries, months of work, and the vast majority of peptides tested turn out to be useless. Campaigns take 5–18 months and cost $100–$1,000+ per validated hit.
Structure-based design tools require high-resolution 3D structures that simply don't exist for most druggable targets, especially GPCRs — the most therapeutically important protein family.
No existing platform — AI-driven, structure-based, or sequence-based — can discover previously unknown binding sites on a target and design the corresponding binders.
A novel ab initio engine that predicts protein-peptide interactions from first principles. Just give it an amino acid sequence.
Provide a target amino acid sequence. No solved structure, no template, no prior screening data required.
XenoProt maps all possible binding sites — including non-obvious, dynamic pockets — and generates 25k–50k ranked peptide binders. 100× fewer than traditional HTS.
Top candidates go straight to array and cell-based assays. Over 10% functional hit rate demonstrated — ready for lead optimisation.
Physics-informed generation and ranking of peptide libraries replaces brute-force screening. Smaller, enriched libraries deliver dramatically higher hit rates at a fraction of the cost.
Systematic exploration of target surfaces beyond canonical sites. Identifies binding regions and complementary binder complexes not apparent from any single static structure.
Analyses how binding landscapes change across multiple conformational states of a target protein, revealing state-dependent pockets that no other platform can access.
Whether you're exploring a managed screening campaign or a deeper research collaboration, we'd love to hear about your target and how XenoProt can help.